Journal List > J Korean Soc Spine Surg > v.22(4) > 1076069

Lee, Jin, and Lee: Conservative Treatment of Osteoporotic Spinal Fractures

Abstract

Study Design

Literature review.

Objectives

To present updated information on the conservative treatment of osteoporotic spinal fractures (OSFs).

Summary of Literature Review

The treatments of osteoporotic spinal fractures are bed rest, pain medication, bracing, exercise and rehabilitation, and osteoporosis medication. However, there is disagreement about the outcomes of these treatments.

Materials and Methods

Review of the relevant literature.

Results

In the case of osteoporotic spinal fractures, analgesic administration, bracing, physical therapy, and exercise should be conducted. In order to prevent secondary fractures, bisphosphonates, selective estrogen receptor modulators, strontium ranelate, or parathyroid hormone, which has proven efficacy with respect to the prevention of secondary fractures, should be prescribed.

Conclusions

We should actively prevent the occurrence of secondary fractures with fracture healing by implementing a proven effective treatment for osteoporotic spinal fractures.

REFERENCES

1. Robin H, Juliet M. A new system for grading recommen-dations in evidence based guidelines. BMJ. 2001; 323:334–6.
crossref
2. Gerdhem P. Osteoporosis and fragility fractures: Vertebral fractures. Best Pract Res Clin Rheumatol. 2013; 7:743–55.
crossref
3. Cherubiono P, Sarzi-Puttini P, Zuccaro SM, et al. The management of chronic pain in important patient sub-groups. Clin Drug Investig. 2012; 32:35–44.
4. Cherasse A, Muller G, Ornetti P, et al. Tolerability of opioids in patients with acute pain due to nonmalignant musculo-skeletal disease. A hospital-based observational study. Joint Bone Spine. 2004; 71:572–6.
crossref
5. Longo UG, Loppini M, Denaro L, et al. Osteoporotic vertebral fractures: current concepts of conservative care. Br Med bull. 2012; 102:171–89.
crossref
6. van Tulder MW, Touray T, Furlan AD, et al. Muscle relax-ants for non-specific low back pain. Cochrane Database Syst Rev. 2003; 2:CD004252.
7. Cauley JA, Black D, Boonen S, et al. Once-yearly zole-dronic acid and days of disability, bed rest, and back pain: randomized, controlled HORIZON Pivotal Fracture Trial. J Bone Miner Res. 2011; 26:984–92.
crossref
8. Rovetta G, Maggiani G, Molfetta L, et al. One-month followup of patients treated by intravenous clodronate for acute pain induced by osteoporotic vertebral fracture. Drugs Exp Clin Res. 2001; 27:77–81.
9. Rovetta G, Monteforte P, Balestra V. Intravenous clodronate for acute pain induced by osteoporotic vertebral fracture. Drugs Exp Clin Res. 2000; 26:25–30.
10. Armingeat T, Brondino R, Pham T, et al. Intravenous pamidronate for pain relief in recent osteoporotic vertebral compression fracture: a randomized double-blind controlled study. Osteoporos Int. 2006; 17:1659–65.
crossref
11. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348:1535–41.
12. Wells GA, Cranney A, Peterson J, et al. Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; 1:CD001155.
crossref
13. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000; 11:83–91.
14. Wells G, Cranney A, Peterson J, et al. Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev. 2008; 1:CD004523.
crossref
15. Delmas PD, Recker RR, Chesnut CH 3rd, et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporos Int. 2004; 15:792–8.
crossref
16. Chesnut CH 3rd, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004; 19:1241–9.
crossref
17. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999; 282:637–45.
18. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res. 2008; 23:1923–34.
crossref
19. Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004; 350:459–68.
crossref
20. Chesnut CH 3rd, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group. Am J Med. 2000; 109:267–76.
21. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001; 344:1434–41.
crossref
22. Cheng MH, Chen JF, Fuh JL, et al. Osteoporosis treatment in postmenopausal women with preexisting fracture. Tai-wan J Obstet Gynecol. 2012; 51:153–66.
crossref
23. Eastell R, Nickelsen T, Marin F, et al. Sequential treatment of severe postmenopausal osteoporosis after teriparatide: final results of the randomized, controlled European Study of Forsteo (EUROFORS). J Bone Miner Res. 2009; 24:726–36.
crossref
24. Kim HJ, Yi JM, Cho HG, et al. Comparative study of the treatment outcomes of osteoporotic compression fractures without neurologic injury using a rigid brace, a soft brace, and no brace: a prospective randomized controlled non-inferiority trial. J Bone Joint Surg Am. 2014; 96:1959–66.
25. Rzewuska M, Ferreira M, McLachlan AJ, et al. The efficacy of conservative treatment of osteoporotic compression fractures on acute pain relief: a systematic review with meta-analysis. Eur Spine J. 2015; 24:702–14.
crossref
26. Howe TE, Howe TE, Rochester L, et al. Exercise for improving balance in older people. Cochrane Database Syst Rev. 2011; 11:CD000333.
crossref
27. Gillespie LD, Robertson MC, Gillespie WJ, et al. Interventions for preventing falls in older people living in the com-munity. Cochrane Database Syst Rev. 2012; 9:CD007146.
crossref
28. Giangregorio LM, Macintyre NJ, Thabane L, et al. Exercise for improving outcomes after osteoporotic vertebral fracture. Cochrane Database Syst Rev. 2013; 1:CD008618.
crossref
29. Bergland A, Thorsen H, Kå resen R. Effect of exercise on mobility, balance, and health-related quality of life in osteoporotic women with a history of vertebral fracture: a randomized, controlled trial. Osteoporos Int. 2011; 22:1863–71.
crossref
30. Gold DT, Shipp KM, Pieper CF, et al. Group treatment improves trunk strength and psychological status in older women with vertebral fractures: results of a randomized, clinical trial. J Am Geriatr Soc. 2004; 52:1471–8.
crossref
31. Papaioannou A, Adachi JD, Winegard K, et al. Efficacy of home-based exercise for improving quality of life among elderly women with symptomatic osteoporosis-related vertebral fractures. Osteoporos Int. 2003; 14:677–82.
crossref
32. Bennell KL, Matthews B, Greig A, et al. Effects of an exercise and manual therapy program on physical impairments, function and quality-of-life in people with osteoporotic vertebral fracture: a randomised, single-blind controlled pi-lot trial. BMC Musculoskelet Disord. 2010; 11:36. Available from:. http://www.biomedcentral.com/1471-2474/11/36.
crossref

Table 1.
Levels of Evidence.
1++ High quality meta-analyses, systematic reviews of RCTs, or RCTs with a very low risk of bias
1+ Well conducted meta-analyses, systematic reviews of RCTs, or RCTs with a low risk of bias
1- Meta-analyses, systematic reviews or RCTs, or RCTs with a high risk of bias
2++ High quality systematic reviews of case-control or cohort studies or High quality case-control or cohort studies with a very low risk of confounding, bias, or chance and a high probability that the relationship is causal
2+ Well conducted case-control or cohort studies with a low risk of confounding, bias, or chance and a moderate probability that the relationship is causal
2- Case-control or cohort studies with a high risk of confounding, bias, or chance and a significant risk that the relationship is not causal
3 Non-analytic studies, eg case reports, case series
4 Expert opinion
Table 2.
Grades of Recommendations.
A At least one meta-analysis, systematic review, or RCT rated as 1++ and directly applicable to the target population or a systematic review of RCTs or a body of evidence consisting principally of studies rated as 1+ directly applicable to the target population and demonstrating overall consistency of results
B A body of evidence including studies rated as 2++ directly applicable to the target population and demonstrating overall consistency of results or extrapolated evidence from studies rated as 1++ or 1+
C A body of evidence including studies rated as 2+ directly applicable to the target population and demonstrating overall consistency of results or extrapolated evidence from studies rated as 2++
D Evidence level 3 or 4 or extrapolated evidence from studies rated as 2+
TOOLS
Similar articles